Page 39 - Regarding Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Steel Connect Reports Second Quarter Financial Results Search jobs Second Quarter 2021 Results Net revenue totaled $156.0 million, as compared to $215.5 million in the prior year Net loss was $2.2 million, as compared to a loss of $3.6 million in the prior year Net loss attributable to common stockholders was $2.7 million, as compared to a loss of $4.1 million in the prior year Adjusted EBITDA Net cash used in operating activities was $20.5 million Free Cash Flow * totaled $296.3 million Net revenue totaled $326.0 million, as compared to $440.6 million in the prior year Net loss was $5.7 mil...

Share: BANNOCKBURN, Ill., March 11, 2021 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2020. Given the merger between Option Care Enterprises, Inc. ("Option Care") and BioScrip, Inc. ("BioScrip") to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2...

SAN DIEGO, CA / ACCESSWIRE / March 11, 2021 / RF Industries, Ltd., (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced its financial results for the

Press release content from Accesswire. The AP news staff was not involved in its creation. RF Industries Reports Financial Results for First Quarter of Fiscal 2021; Reiterates Guidance for Year-Over-Year Growth in Full-Year 2021 Revenue March 11, 2021 GMT SAN DIEGO, CA / ACCESSWIRE / March 11, 2021 / RF Industries, Ltd., (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced its financial results for the first quarter of fiscal 2021 ended January 31, 2021. First Quarter Fiscal 2021 Highlights and Operating Results: Net Sales of $10.0 million ...

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner A...